SCOPE 2023: Transforming DE&I Trials
Seagen, an oncology biotech, emphasizes personalization as part of its DE&I strategy.
In this presentation at SCOPE 2023 in Orlando, FL, Gretchen Goller, Senior Director, Head of Patient Recruitment/Retention Solutions and Neha Londono, Director - Clinical Trial Diversity and Inclusion; both with Seagen, highlighted how the oncology biotech is taking a more personalized approach to DE&I in clinical trials.
Seagen uses the acronym INDEPTH (Increasing Diverse Participation in Clinical Trials and Healthcare) to represent its DE&I strategy. There are five pillars:
- Clinical Trial DE&I
- Inclusive trial design
- Patient centric solutions
- Site engagement
- Collaborations: Trusted messengers and patient advocacy
The biotech uses the first two pillars to set goals, which includes gaining a better understanding of impacted patient populations and gathering information from all stakeholders before making a decision.
The final three pillars represent goal execution. Seagen aims to reduce patient burden, ease trial conduct, strategically choose sites, and reinforce its commitment to diversity. There is also a strong emphasis on partnering with patient communities to gain more perspectives.
Both Goller and Londono emphasized breaking traditional siloes is the key for a DE&I-first clinical trial planning process that relies on cross-functional problem-solving. Rather than following a checklist or template, they are focused on conducting trials with a more personalized approach that considers the implications of all stakeholders.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.
